Zoledronic acid re-sensitises gefitinib-resistant lung cancer cells by inhibiting the JAK/STAT3 signalling pathway and reversing epithelial-mesenchymal transition

Studies have shown that suppression of both the JAK/STAT3 pathway and epithelial-mesenchymal transition (EMT) may overturn the resistance of non-small cell lung cancer (NSCLC) cells to gefitinib. Zoledronic acid (ZA) injection is used to treat and prevent multiple forms of osteoporosis, hypercalcemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xibiao, Gao, Yuan, Liu, Qiang, Wan, Lin, Liu, Honglian, Bian, Weiwei, Du, Yun, Huang, Chuying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757092/
https://www.ncbi.nlm.nih.gov/pubmed/33416163
http://dx.doi.org/10.3892/or.2020.7881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757092/
https://www.ncbi.nlm.nih.gov/pubmed/33416163
http://dx.doi.org/10.3892/or.2020.7881

Ejemplares similares